Travere Therapeutics (TVTX) Cash from Investing Activities (2013 - 2026)

Travere Therapeutics has reported Cash from Investing Activities for 14 years, with the latest figure at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 47.81% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (down 77.18% YoY), and the FY2025 full-year result was $27.9 million, down 71.92% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $21.5 million, up from -$104.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $133.3 million in Q3 2023, with the low at -$224.4 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$2.1 million across 5 years, with a median of $10.1 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 597.98% — and 2023, when it surged 1222.73%.
• Travere Therapeutics' Cash from Investing Activities stood at -$36.7 million in 2022, then slumped by 511.3% to -$224.4 million in 2023, then jumped by 64.2% to -$80.3 million in 2024, then tumbled by 30.54% to -$104.8 million in 2025, then surged by 120.55% to $21.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $21.5 million (Q1 2026), -$104.8 million (Q4 2025), and $86.6 million (Q3 2025), per Business Quant data.